CXCR4 and non-small cell lung carcinoma: Neutralization of CXCL12 by an anti-CXCL12 or anti-CXCR4 monoclonal antibody resulted in a significant decrease of NSCLC metastases to several organs including the adrenal glands, liver, lung, brain, and bone marrow [74,75].